126 related articles for article (PubMed ID: 18241981)
1. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.
Nicolini A; Carpi A; Ferrari P; Rossi G
Cancer Lett; 2008 May; 263(1):122-9. PubMed ID: 18241981
[TBL] [Abstract][Full Text] [Related]
2. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
3. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Mouridsen H; Dombernowsky P
Eur J Cancer; 2004 Mar; 40(4):481-6. PubMed ID: 14962712
[TBL] [Abstract][Full Text] [Related]
4. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
5. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Nicolini A; Rossi G; Ferrari P; Carpi A
Biomed Pharmacother; 2014 Mar; 68(2):171-8. PubMed ID: 24491318
[TBL] [Abstract][Full Text] [Related]
8. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
9. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
Cheung KL; Graves CR; Robertson JF
Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
[TBL] [Abstract][Full Text] [Related]
10. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
13. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
Nicolini A; Carpi A; Ferrari P; Pieri L
Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of TPA in breast cancer.
Madeddu G; Farris A; Casu AR; Saiu MA; Eriu R; Costanza C; Arras ML; Costanza C; Campus S
Cancer Detect Prev; 1985; 8(1-2):47-52. PubMed ID: 4064051
[TBL] [Abstract][Full Text] [Related]
16. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
[TBL] [Abstract][Full Text] [Related]
17. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
Sölétormos G; Petersen PH; Dombernowsky P
Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
19. [Determination of the carcinoembryonic antigen (CEA) for predicting the success of therapy in metastatic breast cancer].
Krieger G; Wander HE; Prangen M; Bandlow G; Beyer JH; Nagel GA
Dtsch Med Wochenschr; 1983 Apr; 108(16):610-4. PubMed ID: 6839982
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]